Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $27 from $17 and keeps an Outperform rating on the shares. BioCryst is buying Astria Therapeutics (ATXS) to “supercharge” its earnings growth with long- acting HAE candidate navenibart, the analyst tells investors in a research note. The firm expects 3 month and 6 month navenibart doses to hit in Astria’s ongoing Phase 3 trial in early 2027 and believe its differentiated, long-acting convenience, coupled with impressive efficacy, will drive broad adoption right as BioCryst’s Orladeyo hits its peak penetration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reinstated with a Buy at TD Cowen
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC
- BioCryst’s Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
- BioCryst’s Strategic Acquisition of Astria Therapeutics Boosts Market Position and Financial Outlook
- BioCryst price target raised to $15 from $14 at Jefferies